March 26, 2024
$0.5 million partial underwrite of the Rights Issue & $1.0 million in further debt or equity to be raised by end April 2024
R3D Resources Limited (ASX: R3D) (the Company) (renamed Tartana Minerals Limited) is pleased to provide an update on the 1 for 5 pro rata entitlement offer of New Shares in the Company at an issue price of $0.05 per New Share, as well as 1 attaching Option exercisable at $0.10 expiring 31 December 2025 for each 2 New Shares subscribed for (the Rights Issue) which opened in November 2023.
Key Points:
- Firm commitment received from Breakaway Investment Group (controlled by director Dr Stephen Bartrop) to underwrite the Rights Issue of up to $500,000
- Additional firm commitment received from Breakaway Research (also controlled by director Dr Stephen Bartrop) to raise $1 million for the Company from third party investors through debt, equity or hybrid instruments by 30 April 2024
- Rights Issue to be extended until 10 April 2024 to enable eligible shareholders to participate on the same terms following the underwriting
- Underwriting Agreements, firm commitment agreements, and further disclosures are to be made upon formal documents being executed over the coming days
- Copper Sulphate production at Tartana has restarted and the Company is targeting to achieve a minimum production rate of fifteen bags of Copper Sulphate a week during the month of April 2024
- Production since restart during March has totalled twenty bags
Partial Underwriting of Rights Issue & Firm Commitment to Further Capital Raising
Breakaway Investment Group Pty Ltd (Breakaway Investment), an entity controlled by R3D’s Managing Director, Dr Stephen Bartrop, has provided the Company with a firm commitment to underwrite the Rights Issue to a minimum raise of $500,000 (the Underwriting), subject to formal agreement.
Additionally, Breakaway Research Pty Ltd (Breakaway Research) an entity also controlled by Dr Stephen Bartrop has provided a further firm commitment to raise $1 million for the Company through debt, equity, or hybrid instruments by 30 April 2024 (the $1m Commitment), again subject to formal agreement. To the extent that Shares and Attaching Options are placed, the Company may use shortfall from the Rights Issue for this purpose. The terms of this raising will be settled between the Company and Breakaway Research in the ordinary course. Breakaway Research is an AFSL holder and accordingly the funds are not expected to be raised from Dr Bartrop but rather parties introduced through Breakaway Research. Accordingly, the Company does not expect shareholder approval to be required for the placement of those securities (except if necessary for placement capacity reasons or if the underlying clients are also Chapter 10 parties).
The Company Is in discussions with each of Breakaway Investment and Breakaway Research towards execution of full-form documents to give effect to this commitment. On those discussions resulting in a binding agreement the Company will issue a further Supplementary Prospectus and will provide the requisite disclosure under ASX Listing Rules as to the full terms of this Underwriting and the $1m Commitment.
The Company will ensure that such terms are arms’ length.
Additionally, it is not expected that the Underwriting or $1m Commitment will result in Dr Bartrop materially increasing his holding in R3D with sub-underwriting and sub-commitment arrangements to be put in place by Breakaway Investment and Breakaway Research at their discretion. Neither Breakaway Investment nor Breakaway Research are being paid fees for their commitments to the Company.
The Company expects that the final terms of the $1m Commitment will include a condition precedent that the Company completes production of at least fifteen 1.2 tonne bags of Copper Sulphate a week from 1 April to 28 April 2024 (calculated on average over the period, totalling 60 bags). The directors (excluding Dr Bartrop) have considered this condition, and have formed the view that it is reasonable to the Company and Breakaway Research. Further, the Company is confident that this will be achievable noting that production in March to date has been twenty bags whilst still being impacted by weather conditions.
Commenting on the status of production at Tartana, Dr Bartrop said:
“We are pleased to report that we have recommenced production at Tartana following a prolonged run of unexpected poor weather that limited site access for staff and input materials. Although the weather continues to affect site operations and access, we are confident in achieving a minimum production at Tartana of at least fifteen bags per week, but hopefully well in excess of that as conditions improve.”
Further Extension of Rights Issue
Eligible Shareholders can review the Rights Issue Prospectus and apply from the Company’s website: www.r3dresources.com.au or at www.computersharecas.com.au/r3dnrri.
Having regard to the impending underwriting, the Company intends to further extend the Rights Issue offer open period until 10 April 2024 which will allow time for eligible shareholders to consider participating on the same terms as the Underwriters.
A Supplementary Prospectus in relation to the extension of the Rights Issue offer open period is annexed, and a copy is being lodged with ASIC.
Click here for the full ASX Release
This article includes content from R3D Resources, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
R3D:AU
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
The Conversation (0)
30 June 2022
R3D Resources Limited
Copper, gold, silver and zinc, producer, explorer and developer in Far North Queensland, Australia
Copper, gold, silver and zinc, producer, explorer and developer in Far North Queensland, Australia Keep Reading...
18h
Rich Checkan: Gold Cheap, Silver Cheaper — Now is The Time to Buy
Rich Checkan, president and COO of Asset Strategies International, shares his outlook for gold and silver, saying the metals are currently at sale prices. Both could still go lower, but he encouraged investors to act sooner than later."Take a little of your cash, deploy it now — lock in that... Keep Reading...
18h
Brien Lundin: Gold's "Unique" Bull Market — Major vs. Junior Stocks
Brien Lundin, editor of Gold Newsletter, shares his thoughts on the pullback in gold and silver prices, saying that finding a bottom will take time. If seasonality is in effect this year, he sees that process happening in mid-July to mid-August. "That's really our last chance — our best chance —... Keep Reading...
21h
Precipitate Gold Strengthens Board with Appointment of Dominican Business Leader Pelayo Troncoso and Mining Finance Executive John Wenger
Precipitate Gold Corp. (TSXV: PRG,OTC:PREIF) (OTCQB: PREIF) (the "Company" or "Precipitate") is pleased to announce the appointments of Mr. Pelayo Troncoso and Mr. John Wenger, CPA, to the Company's Board of Directors, effective immediately.Mr. Troncoso is a Dominican Republic national and an... Keep Reading...
15 July
Experts: Gold Pullback Strengthens Bull Market Case
Gold's retreat from recent record highs has done little to dampen long-term optimism among market participants, with speakers on the Precious Metals panel at the Rick Rule Symposium arguing that the current correction is a normal feature of a healthy bull market rather than the beginning of a... Keep Reading...
14 July
Adrian Day: Gold's Top Driver Now, Plus Bullish Stock Setup
Adrian Day, president of Adrian Day Asset Management, breaks down gold's key price headwinds and what could spark a turnaround. "The most important thing is the war. When that ends, one way or the other, the oil price retreats, CPI expectations come down, the dollar comes down and then it's... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00






